LuisGarcía-‐Sevillano
148
65.
matoid arthritis classification criteria.
vi5-‐vi9 (2012).
Disponible en
66.
L.E.; Detert, J.; Bastian, H.; Scherer, H.U.;
0 American College of Rheumatology /
European League Against Rheumatism criteria for rheumatoid arthritis: is it sensible to
lookat levelsof rheumatoid factor?ArthritisRheum63, 1190-‐1199(2011).
67. Humphreys, J.H.; Symmons, D.P. Postpublicationvalidationof the2010AmericanCollegeof
Rheumatology/European League Against Rheumatism classification criteria for
rheumatoidarthritis:wheredowe stand?CurrOpinRheumatol 25, 157-‐163(2013).
68. Hulsemann, J. L.; Zeidler, H. Undifferentiated arthritis in an early synovitis out-‐patient
clinic. ClinExpRheumatol 13, 37-‐43, (1995).
69. Mochan E, Ebell M. H. Predicting rheumatoid arthritis risk in adults with undifferentiated
arthritis. AmFamPhysician77, 1451-‐1453(2008).
70. Lamana, A.; Balsa, A.; Rueda, B.; Ortiz, A. M.; Nuño, L.; Miranda-‐Carus, M. A.; et al. The TT
IsAssociatedwithHighDiseaseActivity
S ONE 7, e43661 (2012). Disponible en
71.
a-‐Carus, E.; López-‐Nevot, M. A.; et al.
the
regulationof antibodies against citr
Res
Ther12, R62(2010). Disponibleen:
72. Lundberg, K.; Bengtsson, C.;Kharlam
and
environmental determinants fo
y
the anticitrullinated protein/pe
2,
652-‐658(2013). Disponibleen:
73. Ravelli, A.; Felici, E.; Magni-‐Man
ts
with antinuclear antibody-‐posi
us
subgroup irrespectiveof thecourseof joint disease. ArthritisRheum52, 826-‐832(2005).
74. Yuasa, S.; Yamaguchi, H.; Nakanishi, Y.; Kawaminami, S.; Tabata, R.; Shimizu, N.; et al.
Treatment responses and their predictors in patients with rheumatoid arthritis treated
withbiological agents. JMed Invest 60, 77-‐90(2013).
75. Willemze, A.;
W.;Trouw, L. A.New biomarkers in rheumatoid
arthritis. Neth
).
76. Disponibleen:
/
77. Welsing, P.
nkels, H. L.; Kiemeney, L. A.; van Riel, P.L. The
relationship b
oint destruction, and functional capacity over the
courseof rheumatoidarthritis. ArthritisRheum44, 2009-‐2017(2001).
78. Anderson, J.K.; Zimmerman, L.; Caplan, L. ; Michaud, K. Measures of rheumatoid arthritis
disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease
Activity, Disease Activity Score (DAS) and Disease Activity Score with 28-‐Joint Counts
(DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI),
Patient Activity Score (PAS) and Patient Activity Score-‐II (PASII), Routine Assessment of
Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and
Rheumatoid Arthritis Disease Activity Index-‐5 (RADAI-‐5), Chronic Arthritis Systemic
Index (CASI), Patient-‐Based Disease Activity ScoreWith ESR (PDAS1) and Patient-‐Based
Disease Activity Score without ESR (PDAS2), and Mean Overall Index for Rheumatoid
Arthritis (MOI-‐RA).ArthritisCareRes63(Suppl 11), S14-‐36(2011).
79. Prevoo, M.L.; van 't Hof, M.A.; Kuper, H.H.; van Leeuwen, M.A.; van de Putte, L.B.;van Riel,
P.L. Modified disease activity scores that include twenty-‐eight-‐joint counts. Development
and validation in a prospective longitudinal study of patients with rheumatoid
arthritis.ArthritisRheum38, 44-‐48(1995).
80. Hochberg, M. C.; Chang, R. W.; Dwosh, I.; Lindsey, S.; Pincus, T.; Wolfe F. The
AmericanCollege of Rheumatology 1991 revised criteria for the classification of global
functional status inrheumatoidarthritis. ArthritisRheum35, 498-‐502(1992).
81. Emery, P.; Breedveld, F.C.; Hall, S.; Durez, P.; Chang, D.J.; Robertson, D.; et al. Comparisonof
methotrexatemonotherapywith a combination of methotrexate and etanercept in active,
early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-‐blind,
parallel treatment trial. Lancet 372, 375-‐382(2008).
